Notably, the combined exposure of CLL cells to selinexor and idelalisib further increased the nuclear concentrations of FOXO3A and significantly reduced the nuclear activity of NF-kB compared to each single agent, thus explaining from a molecular standpoint, the synergism of this drug combination. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.